Chronic Myeloid Leukemia Coverage from Every Angle

Newly Diagnosed CML: Link Between BMI and Outcomes?

By: Joseph Fanelli
Posted: Tuesday, November 10, 2020

According to findings presented during the 2020 Society of Hematologic Oncology (2020) Annual Meeting (Abstract CML-023), patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) who have a high body mass index (BMI; ≥ 25 mg/m2) had a significantly faster time to response when treated with dasatinib than when treated with imatinib. Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that patients with a normal BMI (≤ 25 mg/m2) had better results with dasatinib, though not significantly, in this post hoc analysis of the phase III DASISION study.

“These findings highlight the importance of considering high BMI as a comorbid condition that could influence treatment outcomes,” the authors concluded. “However, additional validation is necessary to define the overall impact of BMI as a prognostic factor in patients with chronic-phase CML.”

In this retrospective analysis, the authors focused on 519 patients with treatment-naive chronic-phase CML. Patients were classified as having a high or normal BMI. Of those with a high BMI, 109 were treated with dasatinib, and 107 were treated with imatinib. Among those with a normal BMI, 147 received dasatinib, and 147 received imatinib.

For patients with a high BMI, the rates of complete cytogenetic response (CCyR) were 84% with dasatinib and 79% with imatinib. Major molecular response rates and molecular response 4.5 rates were also significantly higher with dasatinib than with imatinib, the authors found. The median time to CCyR for those treated with dasatinib was 3.1 months, compared with 6.1 months with imatinib.

For patients with a normal BMI, the CCyR rate was 82% with dasatinib and 78% with imatinib, with a median time to CCyR of 5.6 months and 6.0 months, respectively. Additionally, in a multivariate analysis, the rate of major molecular response time favored dasatinib over imatinib across subgroups in patients with a high BMI, as well as with a normal BMI (although to a lesser extent).

Disclosure: No disclosure information for the study authors was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.